The Medical Letter on Drugs and Therapeutics
Transdermal Methylphenidates (Daytrana) for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

A transdermal patch formulation of methylphenidate (Daytrana – Noven/Shire) has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old. Like other methylphenidate products, the patch is a schedule II controlled substance. According to the manufacturer, it will be available in pharmacies by the end of June.

PHARMACOKINETICS — After application of the patch, methylphenidate is not detected in plasma for about 3 hours (range 1-6 hours). Plasma concentrations of the more pharmacologically active d-enantiomer (d-MPH) peak after about 7-9 hours. In children, following a single transdermal methylphenidate application of about 9 hours, plasma concentrations were similar to those found with equivalent doses of long-acting oral methylphenidate (Concerta), but after repeat daily dosing, concentrations were almost double those of the ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Transdermal Methylphenidates (Daytrana) for ADHD
Article code: 1237a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian